Recent Posts

Abbott Withdraws Diet Pill Meridia In United States, Canada
Posted on 8 Oct 2010 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. — (AP) Abbott Laboratories said Friday it will withdraw its diet pill Meridia in the U.S. and Canada, after coming under pressure from health regulators who say the drug increases the risk of heart attack and stroke in patients... Read More

7th Circuit Says Motion To Consolidate Depakote Suits Triggers CAFA Jurisdiction
Posted on 17 Oct 2012 by Tom Moylan

CHICAGO - Resolving a split between two district courts, the Seventh Circuit U.S. Court of Appeals on Oct. 16 ruled that plaintiffs' motions to consolidate 10 Illinois state court cases involving Abbott Laboratories' anti-seizure drug Depakote... Read More

Abbott Withdraws Diet Drug Meridia From U.S. Market
Posted on 8 Oct 2010 by Tom Moylan

ABBOTT PARK, Ill. - (Mealey's) After an unfavorable assessment by a Food and Drug Administration expert committee regarding cardiovascular risk, Abbott Laboratories on Oct. 8 agreed with an FDA request to withdraw the weight-loss drug Meridia (sibutramine... Read More

Abbott To Pay $1.5 Billion In Civil, Criminal Penalties For Depakote Off-Label Promotion
Posted on 8 May 2012 by Tom Moylan

ABINGDON, Va. - Abbott Laboratories Inc. on May 7 pleaded guilty to one misdemeanor criminal charge and agreed to pay $1.5 billion in criminal fines, civil penalties and forfeiture for off-label marketing its anti-epilepsy drug Depakote despite knowing... Read More

Williams Mullen: Corporate Spin-Off, New Retirement Plan Did Not Violate Employees’ Rights Under ERISA
Posted on 16 Feb 2012 by Williams Mullen

Nauman v. Abbott Laboratories , No. 10-2272 (7th Cir. February 3, 2012) B y Mark S. Thomas and Robert W. Shaw The U. S. Court of Appeals for the Seventh Circuit has affirmed a trial judgment against a class of former employees of Abbott Laboratories... Read More

Illinois Jury Awards $2.2Million To Widower In 1st Humira Infection Case To Go To Trial
Posted on 10 May 2013 by Tom Moylan

CHICAGO - (Mealey's) An Illinois state court jury on May 9 found Abbott Laboratories negligent and ordered it to pay a plaintiff $2,244,063 for a near-fatal infection his late wife suffered while taking the rheumatoid arthritis drug Humira, according... Read More

Boehringer Ingelheim Pays $95 Million To Settle Off-Label, Kickback Claims In Civil Suit
Posted on 27 Oct 2012 by Tom Moylan

BALTIMORE — Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to the federal government to resolve civil allegations that it marketed three drugs for off-label uses, promoted high doses of two drugs and paid kickbacks to health care... Read More

Kos Pharmaceuticals Pays $41M For Kickbacks, Off-Label Promotion Of Cholesterol Drugs
Posted on 9 Dec 2010 by Tom Moylan

BATON ROUGE, La. - (Mealey's) The Kos Pharmaceuticals subsidiary of Abbott Laboratories Inc. on Dec. 7 entered into a deferred prosecution agreement and agreed to pay a total of $41 million in criminal penalties and False Claims Act settlement for... Read More